For example, Fas is one of the major targets of lopinavir-ritonavir – a combination HIV protease inhibitor (Sorbera et al., 2020); clinical trials of lopinavir-ritonavir failed to provide any therapeutic benefits beyond standard care in hospitalised COVID-19 patients (Cao et al., 2020). This evidence concerns the gene FAS and COVID-19.